Stereotactic body radiotherapy (SBRT) has been reported as an attractive option for cases of failed catheter ablation of ventricular tachycardia (VT) in structural heart disease. However, even this strategy can fail for various reasons. For the first time, this case series describes three re-do cases of SBRT which were indicated for three different reasons. The purpose in the first case was the inaccuracy of the determination of the treatment volume by indirect comparison of the electroanatomical map and CT scan. A newly developed strategy of co-registration of both images allowed precise targeting of the substrate. In this case, the second treatment volume overlapped by 60% with the first one. The second reason for the re-do of SBRT was an unusual character of the substrate–large cardiac fibroma associated with different morphologies of VT from two locations around the tumor. The planned treatment volumes did not overlap. The third reason for repeated SBRT was the large intramural substrate in the setting of advanced heart failure. The first treatment volume targeted arrhythmias originating in the basal inferoseptal region, while the second SBRT was focused on adjacent basal septum without significant overlapping. Our observations suggested that SBRT for VT could be safely repeated in case of later arrhythmia recurrences (i.e., after at least 6 weeks). No acute toxicity was observed and in two cases, no side effects were observed during 32 and 22 months, respectively. To avoid re-do SBRT due to inaccurate targeting, the precise and reproducible strategy of substrate identification and co-registration with CT image should be used.
Aims Catheter ablation (CA) for atrial fibrillation (AF) has a considerable risk of procedural complications. Major vascular complications (MVCs) appear to be the most frequent. This study investigated gender differences in MVCs in patients undergoing CA for AF in a high‐volume tertiary center. Methods A total of 4734 CAs for AF (65% paroxysmal, 26% repeated procedures) were performed at our center between January 2006 and August 2018. Patients (71% males) aged 60 ± 10 years and had a body mass index of 29 ± 4 kg/m2 at the time of the procedure. Radiofrequency point‐by‐point ablation was employed in 96.3% of procedures with the use of three‐dimensional navigation systems and facilitated by intracardiac echocardiography. Pulmonary vein isolation was mandatory; cavotricuspid isthmus and left atrial substrate ablation were performed in 22% and 38% procedures, respectively. MVCs were defined as those that resulted in permanent injury, required intervention, or prolonged hospitalization. Their rates and risk factors were compared between genders. Results A total of 112 (2.4%) MVCs were detected: 54/1512 (3.5%) in females and 58/3222 (1.8%) in males (p < .0001). On multivariate analysis, lower body height was the only risk factor for MVCs in females (p = .0005). On the contrary, advanced age was associated with MVCs in males (p = .006). Conclusion Females have a higher risk of MVCs following CA for AF compared to males. This difference is driven by lower body size in females. Low body height in females and advanced age in males are independent predictors of MVCs. Ultrasound‐guided venipuncture lowered the MVC rate in males.
Background The progression of parasympathetic denervation of the atrioventricular node (AVN) during cardioneuroablation (CNA) can be evaluated by extracardiac vagal stimulation (ECVS). The right vagus nerve is usually used for stimulation (R-ECVS) because the right jugular vein is easily accessible. However, the AVN node is predominantly under the control of the left vagus nerve. Purpose To highlight the importance of left vagus stimulation (L-ECVS) for effective AVN denervation. Methods Both R-ECVS and L-ECVS (frequency: 50 Hz; pulse width: 0.05 ms; output 1 V / 1 kg; max. 70 V, duration 5 s) was attempted in 80 patients (age: 41±12 years, 45% men) undergoing CNA with stepwise strategy consisting of ablation of right anterior ganglionated plexus (RAGP) followed by ablation of posteromedial left ganglionated plexus (PMLGP). The study objective was the AVN response to L-ECVS (evaluated as the max. R-R interval during stimulation train) at the point when AVN non-reactivity to R-ECVS was achieved. Results A total of 59 patients were suitable for the analysis. Of the remaining 21 patients, left (n=14) or right (n=2) jugular veins were not accessible, AVN non-reactivity to L-ECVS was achieved before non-reactivity to R-ECVS (n=4), or AVN denervation was not achieved at all (n=1). At baseline, the AVN response was identical for R-ECVS (max. R-R median: 6.9 s, interquartile range [IQR]: 5.7–8.2 s) and L-ECVS (median: 7.1 s, IQR: 6.0–8.3 s), P=0.44. AVN non-reactivity to R-ECVS was present already at baseline (n=2); was achieved after ablation of RAGP (n=14), after ablation PMLGP (n=38), or after extensive ablation (n=5). At the point of AVN non-reactivity to R-ECVS, the response of AVN to L-ECVS was as follows: none (n=25), 2: 1 AV block (n=13) or complete AV block (n=21). The corresponding median of max. R-R interval was: 1.2 s, IQR: 0.6–4.8 s distributed as shown in Figure 1. Conclusions In 34/59 (58%) patients, significant AVN response to L-ECVS persists after reaching AVN non-reactivity to R-ECVS. Stimulation of both vagal nerves tightens the procedural endpoint and may increase the clinical efficacy of CNA, especially in patients with dominant AVN disorder. Funding Acknowledgement Type of funding sources: None.
Background Radiofrequency catheter ablation of posteromedial left ganglionated plexus is a critical step to eliminate the vagal input to the atrioventricular node (AVN) for the treatment of symptomatic episodes of functional AV block. This ganglionated plexus can be effectively targeted from the coronary sinus (CS) or from the endocardial aspect of the right (RA) and left (LA) atria. Purpose We investigated the effect of ablation at individual sites on the suppression of parasympathetic modulation of AVN. Methods The study included 20 patients (age: 42±13 years, 45% males) who underwent cardioneuroablation in general anesthesia. Posteromedial left ganglionated plexus was ablated from [1] the CS (proximal 2-cm segment), [2] the RA aspect (between the fossa ovalis and inferior vena cava), and [3] the LA aspect (middle bottom part adjacent to inferior rim of fossa ovalis). Patients were randomly (1:1) assigned to CS-to-RA or RA-to-CS ablation order. LA ablation was always the last step. The response to extracardiac vagus nerve stimulation (ECVS; 50 Hz, 0.05 ms, 1 V/kg [<70V], 5 s) while atrial pacing (100 bpm) was recorded at baseline and after each ablation step. The number of non-AV-conducted beats during the ECVS was considered a measure of AV nodal denervation. Both right and left vagus nerves were sequentially stimulated and the stronger response of the AV node was taken into account. Results Temporal development of outcome measure with the progression of ablation is shown in Figure 1. CS ablation resulted in much stronger AV nodal denervation compared to RA ablation (P=0.02). However, RA ablation still provided some effect on top of CS ablation. The combination of CS + RA ablation resulted in complete AVN denervation in 8 (40%) patients. Subsequent LA ablation increased the number of denervated patients to 14 (70%). Two more patients were subsequently denervated by ablation elsewhere. In four patients, AVN denervation was not achieved but their responsiveness to ECVS was significantly suppressed compared to the baseline. Conclusions All ablation clusters targeting posteromedial ganglionated plexus convey complementary effects. Biatrial cardioneuroablation seems essential for efficacious suppression of parasympathetic modulation of AVN. Funding Acknowledgement Type of funding sources: None.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.